Table 2.
Subgroup analyses of SII.
| Subgroup | No. of studies | HR (95% CI) | P | Heterogeneity | Model | |
|---|---|---|---|---|---|---|
| I2 (%) | Ph | |||||
| Overall survival | ||||||
| Country | ||||||
| China | 6 | 1.58 (1.35–1.84) | <.001 | 39.6 | 0.142 | Fixed |
| Japan | 1 | 3.28 (1.29–8.32) | .012 | – | – | – |
| Sample size | ||||||
| ＞200 | 2 | 1.43 (1.21–1.70) | <.001 | 0 | 0.469 | Fixed |
| <200 | 5 | 2.46 (1.77–3.41) | <.001 | 0 | 0.769 | Fixed |
| Cut-off | ||||||
| ＞484.5 | 3 | 2.03 (1.20–3.44) | .009 | 59.8 | 0.083 | Random |
| ≤484.5 | 4 | 1.79 (1.30–2.45) | <.001 | 40.7 | 0.167 | Fixed |
| Analysis | ||||||
| Multivariate | 5 | 1.78 (1.30–2.45) | <.001 | 51.1 | 0.085 | Random |
| Univariate | 2 | 2.39 (1.26–4.53) | .008 | 0 | 0.358 | Fixed |
| Disease-free survival | ||||||
| Country | ||||||
| China | 4 | 1.64 (0.95–2.82) | .073 | 75.3 | 0.007 | Random |
| Japan | 1 | 4.10 (1.63–10.32) | .003 | – | – | – |
| Sample size | ||||||
| ＞200 | 1 | 0.94 (0.66–1.33) | .729 | – | – | – |
| <200 | 4 | 2.28 (1.65–3.15) | <.001 | 19.7 | 0.291 | Fixed |
| Cut-off | ||||||
| ＞484.5 | 2 | 2.30 (0.83–6.39) | .109 | 69.7 | 0.069 | Random |
| ≤484.5 | 3 | 1.74 (0.84–3.62) | .138 | 83.5 | 0.002 | Random |
| Analysis | ||||||
| Multivariate | 5 | 1.90 (1.11–3.27) | .02 | 76.4 | 0.002 | Random |
| Univariate | 0 | – | – | – | – | – |
HR = hazard ratio, SII = systemic immune-inflammation index.